Virus Therapy Shrinks Skin Cancers in Early Trial

Adults with advanced skin cancers saw tumor responses in a small early study of an intratumoral oncolytic virus.

Updated on Nov. 7, 2026 in Cancer

Isometric editorial illustration of spiky viral particles pressing into pale tissue that breaks apart, on a plain dark field.
Early data from a small phase 1/1b trial showed the intratumoral virus VET3-TGI shrank advanced skin cancers in patients who had run out of standard options. AI Illustration. Upload story photo >

Early data from a phase 1/1b trial of VET3-TGI, an intratumoral oncolytic vaccinia virus, showed tumor responses in patients with advanced solid tumors, particularly skin cancers. The findings were presented at the 2026 SITC Annual Meeting and involve a small group of patients, so they remain preliminary for adults with advanced cancers who have run out of standard options.

Why it matters

Patients with advanced solid tumors, and especially those whose cancers have stopped responding to anti-PD-1 or PD-L1 immunotherapy, have limited options once standard treatments fail. The early signal in cutaneous cancers suggests a new approach that works through the immune system may be worth further study in this group.

This interim analysis from a phase 1/1b trial included 20 patients with advanced solid tumors, with efficacy assessed in 12 who had sufficient follow-up. Blinded independent central review found a 42% objective response rate in the evaluable group, with the cutaneous subgroup reaching 71%.

The players

University of Pittsburgh Medical Center Hillman Cancer Center

A major U.S. cancer research and treatment center that is affiliated with the presenting physician and contributes to oncology trials and immunotherapy research.

The details

VET3-TGI is an oncolytic vaccinia virus, meaning a modified virus that infects and destroys tumor cells, engineered to carry a TGF-β inhibitor and interleukin-12. The drug is injected directly into tumors, and responses were also seen in lesions that were not injected, suggesting an effect that reaches beyond the treated site. Its combination of immune-stimulating and immune-suppressing-pathway-blocking components is designed to help the body's own immune system recognize and attack cancer cells.

Timeline

  1. The data cutoff for the 20 treated patients was September 2026.

  2. The efficacy data were presented at the 2026 SITC Annual Meeting.

Health Landscape

Anti-PD-1 and PD-L1 checkpoint inhibitors have become a standard part of treatment for many advanced cancers, but many patients eventually progress on them. Oncolytic viruses and other immune-based strategies are being explored as ways to restart or broaden immune responses in those patients.

If you have an advanced solid tumor that has stopped responding to immunotherapy, this early research is worth knowing about as an option that may be studied further, and it is worth asking your oncologist whether clinical trials for intratumoral therapies could be appropriate. These findings come from a very small group of patients, so they should not be taken as a reason to change your current treatment; any decision is worth discussing with your doctor.

The takeaway

Early responses in advanced cancers, particularly skin cancers, show that intratumoral immune-based therapies are being tested in patients with few remaining options. If you are living with an advanced cancer, ask your oncologist whether clinical trials are a possibility for you.

What happens next

Additional studies are planned to confirm clinical activity of VET3-TGI in cutaneous malignancies, though no specific dates were provided in the source.

Further reading

For broader context on how new cancer approaches are tested and compared, explore our Cancer coverage.

Source note: This article includes information reported by OncLive.